openPR Logo
Press release

Experienced Venture Capitalist/Pharma Manager Joins Apeiron`s Business Development Team

01-10-2011 01:54 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Apeiron

Vienna (Austria), 10 January 2011 - APEIRON Biologics AG (Apeiron) today announced that Patrick Burgermeister, a seasoned venture capital and pharma manager will play a leading role in the company's business development activities. He will be engaged in identification and evaluation of new projects, in-licensing/out-licensing activities, portfolio assessment and sourcing new financing opportunities. Patrick Burgermeister has a dual background in business administration and molecular biology and brings in extensive industry experience from the areas of biotech, pharma, medtech, banking and venture capital.

Commenting on the appointment of Mr. Burgermeister, Hans Loibner, CEO of Apeiron, stated: "As one of the consequences of our major licensing deal with GSK in early 2011 Apeiron presently enlarges both its portfolio and its manpower. Having Patrick on board is a valuable asset for our expanding company. Patrick's knowledge, his skills as well as his wide network of contacts throughout the industry will make a significant contribution to the continuation of Apeiron's success."

Patrick Burgermeister added: "I have been following Apeiron's development and recent success closely and was always intrigued by their projects and abilities. I am excited to work with of one of the most promising biotech companies in Europe."

About Patrick Burgermeister:
Patrick Burgermeister has a dual background in business administration (University of St. Gallen, Switzerland) and molecular biology (Biocentre, Basel, Switzerland). Before working with Apeiron he sourced deals and lead numerous scientific and financial due diligences of (mostly) early-stage European biotech and medtech companies at the venture capital group BioMedPartners (funds over CHF 250 mio). For two years, he was CFO of one portfolio company and board representative of an other. Before that Patrick Burgermeister served as Senior Portfolio Manager at Novartis where he was responsible for the evaluation and strategic ranking of development projects. He acted as interface to the finance department and improved the NPV valuation methodology.
His industrial career started as strategic planner for the medtech company Jomed. Subsequently, he became Senior Financial Analyst at Zürcher Kantonalbank (ZKB) where he was responsible for pharma research and built up biotech research. He also advised their health care fund (size approx. CHF 1 bio).

About Apeiron:
Apeiron Biologics AG is a privately financed Biotech company based in Vienna. In January 2010, the then lead product APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme-based biotherapeutic for treatment of Acute Respiratory Distress Syndrome (ARDS) and a series of other diseases, was licensed out to GSK in a milestone-based agreement for approx. EUR 236 million. Currently, building on an existing set of innovative in-house projects, Apeiron is expanding its portfolio with clinical projects up to Phase II with a focus on biologic / immunologic therapy of cancer. In November 2010 the company concluded its first in-licensing deal: Recombinant human Superoxide Dismutase (SOD), a naturally occurring enzyme with important antioxidant properties.

Contact Apeiron:
Hans Loibner, Ph.D.,
CEO
APEIRON Biologics AG
Campus-Vienna-Biocenter 5
1030 Vienna, Austria
T +43 / 1 / 865 6577 100
E hans.loibner@apeiron-biologics.com
W www.apeiron-biologics.com

Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Mariannengasse 8
1090 Vienna
Austria
T +43 / 1 / 505 70 44
E contact@prd.at
W www.prd.at

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Experienced Venture Capitalist/Pharma Manager Joins Apeiron`s Business Development Team here

News-ID: 157962 • Views:

More Releases from Apeiron

05-15-2017 | Health & Medicine
Apeiron
Marketing Approval for Children’s Cancer Immunotherapy in the EU: Outstanding …
May 8, 2017, The European Commission has granted marketing authorization for "Dinutuximab beta Apeiron", an antibody-based immunotherapy of the rare pediatric cancer neuroblastoma. Thanks to the Vienna-based Biotech company Apeiron Biologics AG ("Apeiron") patients in Europe are now offered an additional treatment option with a promising therapy – a result of a collaborative effort of management and employees, academic institutions, Austrian private investors, business angels as well as public and
10-05-2016 | Health & Medicine
APEIRON
Neuroblastoma: APEIRON Grants EUSA Pharma Global Rights to Immunotherapy
Vienna, Austria, 04 October 2016 – APEIRON Biologics AG grants EUSA Pharma, UK exclusive global commercialization rights to the oncology product ISQETTE®. ISQETTE® is an antibody-based immunotherapy with orphan drug designation for the treatment of pediatric neuroblastoma. The therapy has been developed by APEIRON together with an academic network including the St. Anna Children's Cancer Research Institute in Vienna. APEIRON Biologics AG, a private biotech company based in Vienna, Austria, developing
12-17-2012 | Health & Medicine
Apeiron
Apeiron Biologics Establishes Biotech-Spinoff Attoquant Diagnostics
APEIRON Biologics AG (Apeiron) today announced the launch of Attoquant Diagnostics GmbH (Attoquant) as a subsidiary. Attoquant will globally commercialize its already successfully marketed peptide analytics service RAS-Fingerprint™ and further develop the underlying platform technology. Vienna-based biotech company APEIRON Biologics AG (Apeiron) today announced the establishment of a subsidiary that will globally commercialize the peptide analytics service RAS-Fingerprint™ which has been developed by Apeiron and already marketed successfully. Attoquant Diagnostics GmbH

All 4 Releases


More Releases for Patrick

Patrick Robertelli Reflects on Union Life and Family
New Jersey - Patrick Robertelli, a distinguished Teamsters Union driver and committed family man, contemplates the journey that has forged his identity, characterized by diligence, fidelity, and profound community connections. Image: https://www.abnewswire.com/upload/2025/07/523d03da639c8f583994bad816b25797.jpg Robertelli's narrative exemplifies persistence, honesty, and steadfast dedication to both his job and family, forged over decades in the transportation sector and marked by a significant local community involvement. Patrick was born and reared in Hasbrouck Heights, New Jersey, in a
06-25-2025 | Food & Beverage
Arietta
Patrick Nyeholt Promoted to Winemaker for Arietta Wine
(June 24; NAPA, Calif.)-Fritz Hatton and Caren Frutig Hatton, proprietors of Napa-based Arietta Wine, are pleased to announce the appointment of Patrick Nyeholt to the position of winemaker. For over a decade, Patrick has been an integral part of the Arietta team, having joined as assistant winemaker in 2016 before being promoted to associate winemaker in 2020. The appointment marks Nyeholt's second role as winemaker, following Caren Frutig Hatton's Nestweaver
Patrick Farm Painting Serving Syracuse New York
Image: https://www.globalnewslines.com/uploads/2025/05/1748011565.jpg Barn here in Upstate New York that was painted, stained and has a fresh roof coating. This was done By Patrick Farm Painting Patrick Farm Painting Barn, Storage Tank, and Metal Roof Painting Services to Syracuse and Upstate New York Syracuse, NY - Patrick Farm Painting, a trusted name in agricultural and industrial painting, is proud to announce the expansion of its professional barn painting, storage tank painting, and
Patrick Delehanty Champions Innovative Engineering Practices
Image: https://www.globalnewslines.com/uploads/2024/12/1734670606.jpg Patrick Delehanty, Coweta, Oklahoma Entrepreneur and Air Force Veteran Highlights the Importance of Technology and Efficiency in Modern Industry Patrick Delehanty, a U.S. Air Force veteran and founder of Delco Holdings, LLC [https://www.delcodevgru.com/], is urging businesses and engineers to embrace advanced engineering practices and cutting-edge technologies to enhance productivity and meet the demands of a rapidly changing world. Drawing from his extensive background in engineering, entrepreneurship, and federal contracting, Delehanty
Netscribes Welcomes Patrick Tobin as Senior Vice President - Americas
Netscribes, a global research & analytics and digital solutions firm is pleased to announce the appointment of Patrick Tobin as Senior Vice President - Americas. With an exceptional track record of driving growth and empowering teams, Patrick Tobin brings more than 30 years of experience in strategy, leadership, and business development. In his most recent role at Evalueserve, Pat served as the VP of Sales for Data Analytics and Research
Patrick Doczi Now Oversees North American Operations for NGC
Patrick Doczi, a four-year veteran of National Gift Card (NGC), has been named the company’s new Director of North American Operations, a role he sees as being essential to the ongoing development of a highly-focused customer service team. Doczi, who most recently served as the Supervisor of the Activations Department at NGC, says helping all employees embrace a "can do" attitude is what continues to excite him. "It’s fun to see everyone,